Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
gilead sciences
6
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
alzheimer's disease
biotech
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
biogen
bristol-myers squibb
clinical trials
diagnostics
medicare
merck
nonalcoholic steatohepatitis
novartis
pfizer
What
drug
6
×
bio
roundup
nash
acquisitions
biggest
biogen’s
ceo
gilead
new
news
pipeline
sciences
week
adding
aducanumab
albert
alzheimer’s
amyloid
angst
approval
approved
bagged
bets
billions
biogen
biopharmaceutical
boost
bourla
brammer
build
buy
cancer
companies
company
company’s
convo
crispr
daniel
data
Language
unknown
unset
Current search:
drug
×
" gilead sciences "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
To Boost Cancer Pipeline, Gilead Bets at Least $50M on Startup Tango
